XKDCT080 in GCC-positive Recurrent or Refractory Solid Tumors With Single Center, Single Arm, and Dose Escalation
Status:
Recruiting
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to assessing the safety and tolerability of XKDCT080 cells
against recurrent or refractory solid tumors with GCC positivity.This experiment proposes to
enroll 9-18 patients, the experimental drug is a chimeric antigen receptor T cell preparation
targeting GCC.
Secondary purpose of the study
1. Evaluate the pharmacokinetic characteristics of XKDCT080 cells after intravenous
infusion into GCC-positive patients with recurrent or refractory solid tumors;
2. Preliminary Evaluation of the Effectiveness of XKDCT080 Cells in Patients with Recurrent
or Refractory Solid Tumors Positive for GCC;
3. Explore the relationship between cytokines and therapeutic efficacy in patients with
recurrent or refractory solid tumors who are positive for GCC after intravenous infusion
of XKDCT080 cells.